We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · September 17, 2020

Lower Cardiorenal Risk With Sodium–Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients Without Cardiovascular and Renal Diseases

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Lower Cardiorenal Risk With Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients Without Cardiovascular and Renal Diseases: A Large Multinational Observational Study
Diabetes Obes Metab 2020 Sep 07;[EPub Ahead of Print], KI Birkeland, J Bodegard, A Banerjee, DJ Kim, A Norhammar, JW Eriksson, M Thuresson, S Okami, KH Ha, N Kossack, JB Mamza, R Zhang, T Yajima, I Komuro, T Kadowaki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading